Pancreatic Cancer Research

Clinical trialPhase 1 / Phase 2Completed

First-in-Human Study of IMGC936 in Participants With Advanced Solid Tumors

A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation and Expansion Study of IMGC936 (Anti-ADAM9 Antibody Drug Conjugate) in Patients With Advanced Solid Tumors

Outcome
Results posted; no analysis attached
Phase
Phase 1 / Phase 2
Status
Completed
Study type
Interventional
Start
29 October 2020
Ended
28 December 2023
Enrollment
56 participants
Sites
13
Primary outcomes
Dose Escalation Phase: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs); Dose Escalation Phase: Number of Participants With Dose-limiting Toxicities (DLTs) Based on National Cancer Institute (NCI) Common Terminology Criteria for AEs Version 5.0 (CTCAE v5.0); Dose Expansion Phase: Objective Response Rate (ORR) - Percentage of Participants With Objective Response as Assessed by the Investigator Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)
Sponsor type
Industry
Results posted
15 January 2025
Last update
15 January 2025

These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.

Results

Primary endpoint
Results posted; no analysis attachedAs posted on ClinicalTrials.gov ↗, registry record of 15 January 2025
Primary outcome
Dose Escalation Phase: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)Any TEAEs: Dose Escalation - Schedule A: IMGC936 0.5 mg/kg: 3 of 3Any TEAEs: Dose Escalation - Schedule A: IMGC936 1.0 mg/kg: 3 of 3Any TEAEs: Dose Escalation - Schedule A: IMGC936 2.0 mg/kg: 3 of 3Any TEAEs: Dose Escalation - Schedule A: IMGC936 4.0 mg/kg: 3 of 3Any TEAEs: Dose Escalation - Schedule A: IMGC936 5.0 mg/kg: 3 of 3Any TEAEs: Dose Escalation - Schedule A: IMGC936 6.0 mg/kg: 10 of 10Any TEAEs: Dose Escalation - Schedule A: IMGC936 7.0 mg/kg: 9 of 9Any TEAEs: Dose Escalation - Schedule B: IMGC936 2.0 mg/kg: 3 of 3SAEs: Dose Escalation - Schedule A: IMGC936 0.5 mg/kg: 1 of 3SAEs: Dose Escalation - Schedule A: IMGC936 1.0 mg/kg: 0 of 3SAEs: Dose Escalation - Schedule A: IMGC936 2.0 mg/kg: 1 of 3SAEs: Dose Escalation - Schedule A: IMGC936 4.0 mg/kg: 0 of 3SAEs: Dose Escalation - Schedule A: IMGC936 5.0 mg/kg: 1 of 3SAEs: Dose Escalation - Schedule A: IMGC936 6.0 mg/kg: 1 of 10SAEs: Dose Escalation - Schedule A: IMGC936 7.0 mg/kg: 4 of 9SAEs: Dose Escalation - Schedule B: IMGC936 2.0 mg/kg: 2 of 3Values: ParticipantsTime frame: Up to approximately 3 yearsNo analysis posted for this outcome (outcome 1)
DLT/MTD
Dose Escalation Phase: Number of Participants With Dose-limiting Toxicities (DLTs) Based on National Cancer Institute (NCI) Common Terminology Criteria for AEs Version 5.0 (CTCAE v5.0)Dose Escalation - Schedule A: IMGC936 0.5 mg/kg: 0 of 3Dose Escalation - Schedule A: IMGC936 1.0 mg/kg: 0 of 3Dose Escalation - Schedule A: IMGC936 2.0 mg/kg: 0 of 3Dose Escalation - Schedule A: IMGC936 4.0 mg/kg: 0 of 3Dose Escalation - Schedule A: IMGC936 5.0 mg/kg: 0 of 3Dose Escalation - Schedule A: IMGC936 6.0 mg/kg: 0 of 10Dose Escalation - Schedule A: IMGC936 7.0 mg/kg: 0 of 9Dose Escalation - Schedule B: IMGC936 2.0 mg/kg: 0 of 3Values: ParticipantsTime frame: Cycle 1 (21 days for Schedule A and 28 days for Schedule B)No analysis posted for this outcome (outcome 2)
ORR
Dose Expansion Phase: Objective Response Rate (ORR) - Percentage of Participants With Objective Response as Assessed by the Investigator Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)Dose Expansion - NSCLC: IMGC936 6.0 mg/kg: 0 (0 to 0), n = 13Dose Expansion - TNBC: IMGC936 6.0 mg/kg: 0 (0 to 0), n = 6Values: percentage of participants, 95% Confidence IntervalTime frame: Up to approximately 3 yearsNo analysis posted for this outcome (outcome 3)
Participants
Dose Escalation - Schedule A: IMGC936 0.5 mg/kg: 3 started, 3 completedDose Escalation - Schedule A: IMGC936 1.0 mg/kg: 3 started, 3 completedDose Escalation - Schedule A: IMGC936 2.0 mg/kg: 3 started, 3 completedDose Escalation - Schedule A: IMGC936 4.0 mg/kg: 3 started, 3 completedDose Escalation - Schedule A: IMGC936 5.0 mg/kg: 3 started, 3 completedDose Escalation - Schedule A: IMGC936 6.0 mg/kg: 10 started, 10 completedDose Escalation - Schedule A: IMGC936 7.0 mg/kg: 9 started, 9 completedDose Escalation - Schedule B: IMGC936 2.0 mg/kg: 3 started, 3 completedDose Expansion - Non-small Cell Lung Cancer (NSCLC): IMGC936 6.0 mg/kg: 13 started, 13 completedDose Expansion - Triple-negative Breast Cancer (TNBC): IMGC936 6.0 mg/kg: 6 started, 6 completed
Serious adverse events
Dose Escalation - Schedule A: IMGC936 0.5 mg/kg: 1 of 3Dose Escalation - Schedule A: IMGC936 1.0 mg/kg: 0 of 3Dose Escalation - Schedule A: IMGC936 2.0 mg/kg: 1 of 3Dose Escalation - Schedule A: IMGC936 4.0 mg/kg: 0 of 3Dose Escalation - Schedule A: IMGC936 5.0 mg/kg: 1 of 3Dose Escalation - Schedule A: IMGC936 6.0 mg/kg: 1 of 10Dose Escalation - Schedule A: IMGC936 7.0 mg/kg: 4 of 9Dose Escalation - Schedule B: IMGC936 2.0 mg/kg: 2 of 3Dose Expansion - NSCLC: IMGC936 6.0 mg/kg: 4 of 13Dose Expansion - TNBC: IMGC936 6.0 mg/kg: 2 of 6Participants with at least one serious adverse event, of those at risk, as posted
6 secondary outcomes
Dose Escalation and Dose Expansion Phase: Maximum Study Drug Concentration (Cmax)
C1D1: Dose Escalation - Schedule A: IMGC936 0… 14.17 (22), n=3; Dose Escalation - Schedule A: IMGC936 1… 22.21 (5.6), n=3; Dose Escalation - Schedule A: IMGC936 2… 56.69 (14.2), n=3; Dose Escalation - Schedule A: IMGC936 4… 107.2 (9.6), n=3; Dose Escalation - Schedule A: IMGC936 5… 114.8 (30.7), n=3; Dose Escalation - Schedule A and Dose E… 149.5 (21.6), n=29; Dose Escalation - Schedule A: IMGC936 7… 162.4 (23.7), n=9; Dose Escalation - Schedule B: IMGC936 2… 51.74 (9.8), n=3 [geometric mean micrograms/milliliter (μg/mL), Geometric Coefficient of Variation] (first of 3 rows)
Dose Escalation and Dose Expansion Phase: Number of Participants With Antidrug Antibodies…
Dose Escalation - Schedule A: IMGC936 0… 3/3; Dose Escalation - Schedule A: IMGC936 1… 1/3; Dose Escalation - Schedule A: IMGC936 2… 1/3; Dose Escalation - Schedule A: IMGC936 4… 0/3; Dose Escalation - Schedule A: IMGC936 5… 1/3; Dose Escalation - Schedule A: IMGC936 6… 2/10; Dose Escalation - Schedule A: IMGC936 7… 0/9; Dose Escalation - Schedule B: IMGC936 2… 1/3 [Participants]
ORR · Dose Escalation Phase: ORR - Percentage of Participants With Objective Response as …
Dose Escalation - Schedule A: IMGC936 0… 0 (0 to 0), n=3; Dose Escalation - Schedule A: IMGC936 1… 0 (0 to 0), n=3; Dose Escalation - Schedule A: IMGC936 2… 0 (0 to 0), n=3; Dose Escalation - Schedule A: IMGC936 4… 0 (0 to 0), n=3; Dose Escalation - Schedule A: IMGC936 5… 0 (0 to 0), n=3; Dose Escalation - Schedule A: IMGC936 6… 0 (0 to 0), n=10; Dose Escalation - Schedule A: IMGC936 7… 0 (0 to 0), n=9; Dose Escalation - Schedule B: IMGC936 2… 0 (0 to 0), n=3 [percentage of participants, 95% Confidence Interval]
Dose Escalation and Dose Expansion Phase: Duration of Response (DOR) as Assessed by the I…
Dose Escalation - Schedule A: IMGC936 0… NA (NA to NA), n=3; Dose Escalation - Schedule A: IMGC936 1… NA (NA to NA), n=3; Dose Escalation - Schedule A: IMGC936 2… NA (NA to NA), n=3; Dose Escalation - Schedule A: IMGC936 4… NA (NA to NA), n=3; Dose Escalation - Schedule A: IMGC936 5… NA (NA to NA), n=3; Dose Escalation - Schedule A: IMGC936 6… NA (NA to NA), n=10; Dose Escalation - Schedule A: IMGC936 7… NA (NA to NA), n=9; Dose Escalation - Schedule B: IMGC936 2… NA (NA to NA), n=3 [median months, Full Range]
PFS · Dose Expansion Phase: Progression-Free Survival (PFS) as Assessed by the Investigat…
Dose Expansion - NSCLC: IMGC936 6.0 mg/… 2.7 (0.7 to 6.7), n=13; Dose Expansion - TNBC: IMGC936 6.0 mg/kg 1.2 (0.0 to 2.4), n=6 [median months, Full Range]
Dose Expansion Phase: Number of Participants With TEAEs, SAEs, and IMGC936 Related TEAEs …
Any TEAEs: Dose Expansion - NSCLC: IMGC936 6.0 mg/… 13/13; Dose Expansion - TNBC: IMGC936 6.0 mg/kg 6/6 [Participants] (first of 3 rows)

Every value is copied from the trial’s results record at ClinicalTrials.gov. “Statistically significant” describes the posted test only: it does not say which group did better, and nothing here is read from a paper.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

Brief summary public domain (ClinicalTrials.gov)

This study is a Phase 1/2, first-in-human, open-label, dose-escalation, and expansion study designed to characterize the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of IMGC936 administered by intravenous (IV) infusion.

Detailed description public domain (ClinicalTrials.gov)

This is an open-label, dose-escalation, and expansion study to determine the Maximum Tolerated Dose (MTD) and select the recommended Phase 2 dose (RP2D). Dose escalation follows a conventional 3+3 design; successive cohorts of 3 to 6 participants each will be evaluated in sequential escalating doses of single-agent IMGC936. Upon completion of the dose-escalation phase of the study, following determination of the RP2D, up to 5 expansion cohorts may be opened in tumor types selected from those enrolled in dose escalation. Participants with relapsed or refractory, unresectable locally advanced or metastatic solid tumors including non-squamous non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), colorectal cancer (CRC), gastroesophageal cancer, or pancreatic cancer will be enrolled. IMGC936 is administered via IV infusion on Day 1 of Cycle 1 and every subsequent 21-day cycle thereafter, at the assigned dose for each cohort during dose escalation, and at the RP2D for expansion. Infusion duration will vary depending on dose and participant tolerability. Sentinel dosing will be used for the first 2 dose levels of dose escalation. The first administration of IMGC936 in participants at the first 2 dose levels of dose escalation will be staggered by at least 48 hours. The dose-limiting toxicity (DLT) evaluation period is 21 days. Participants may continue on study drug until disease progression, adverse event (AE) requiring discontinuation, DLT during evaluation window, pregnancy, death, investigator decision, lost to follow up (LTFU), major protocol deviation requiring discontinuation, withdrawal of consent, or sponsor, investigator or regulatory agency terminates the study. Tumor assessments are performed every 6 weeks (Q6W) while on study drug then every 12 weeks (Q12W). Tumor assessments continue until discontinuation criteria are met. If feasible, participants who discontinue study drug for reasons other than progressive disease (PD) (e.g., toxicity) should continue to undergo tumor assessments Q12W as post-treatment follow up until evidence of PD, initiation of another anticancer therapy, withdrawal of consent, LTFU, death, or end of study. Post-treatment follow up also includes following ongoing treatment emergent adverse events (TEAEs) until the event has resolved to baseline grade, the event is assessed by the investigator as stable, initiations of another anticancer therapy, withdrawal of consent, LTFU, death, or it has been determined that study drug or participation is not the cause of the AE.

Posted results (ClinicalTrials.gov registry) · primary outcome public domain (ClinicalTrials.gov)

Dose Escalation Phase: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) [Up to approximately 3 years]. Count Of Participants, Participants. Any TEAEs: Dose Escalation - Schedule A: IMGC936 0.5 mg/kg (n=3): 3; Dose Escalation - Schedule A: IMGC936 1.0 mg/kg (n=3): 3; Dose Escalation - Schedule A: IMGC936 2.0 mg/kg (n=3): 3; Dose Escalation - Schedule A: IMGC936 4.0 mg/kg (n=3): 3; Dose Escalation - Schedule A: IMGC936 5.0 mg/kg (n=3): 3; Dose Escalation - Schedule A: IMGC936 6.0 mg/kg (n=10): 10; Dose Escalation - Schedule A: IMGC936 7.0 mg/kg (n=9): 9; Dose Escalation - Schedule B: IMGC936 2.0 mg/kg (n=3): 3. SAEs: Dose Escalation - Schedule A: IMGC936 0.5 mg/kg (n=3): 1; Dose Escalation - Schedule A: IMGC936 1.0 mg/kg (n=3): 0; Dose Escalation - Schedule A: IMGC936 2.0 mg/kg (n=3): 1; Dose Escalation - Schedule A: IMGC936 4.0 mg/kg (n=3): 0; Dose Escalation - Schedule A: IMGC936 5.0 mg/kg (n=3): 1; Dose Escalation - Schedule A: IMGC936 6.0 mg/kg (n=10): 1; Dose Escalation - Schedule A: IMGC936 7.0 mg/kg (n=9): 4; Dose Escalation - Schedule B: IMGC936 2.0 mg/kg (n=3): 2.

Posted results (ClinicalTrials.gov registry) · primary outcome public domain (ClinicalTrials.gov)

Dose Escalation Phase: Number of Participants With Dose-limiting Toxicities (DLTs) Based on National Cancer Institute (NCI) Common Terminology Criteria for AEs Version 5.0 (CTCAE v5.0) [Cycle 1 (21 days for Schedule A and 28 days for Schedule B)]. Count Of Participants, Participants. Dose Escalation - Schedule A: IMGC936 0.5 mg/kg (n=3): 0; Dose Escalation - Schedule A: IMGC936 1.0 mg/kg (n=3): 0; Dose Escalation - Schedule A: IMGC936 2.0 mg/kg (n=3): 0; Dose Escalation - Schedule A: IMGC936 4.0 mg/kg (n=3): 0; Dose Escalation - Schedule A: IMGC936 5.0 mg/kg (n=3): 0; Dose Escalation - Schedule A: IMGC936 6.0 mg/kg (n=10): 0; Dose Escalation - Schedule A: IMGC936 7.0 mg/kg (n=9): 0; Dose Escalation - Schedule B: IMGC936 2.0 mg/kg (n=3): 0.

Posted results (ClinicalTrials.gov registry) · primary outcome public domain (ClinicalTrials.gov)

Dose Expansion Phase: Objective Response Rate (ORR) - Percentage of Participants With Objective Response as Assessed by the Investigator Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) [Up to approximately 3 years]. Number, percentage of participants (95% Confidence Interval). Dose Expansion - NSCLC: IMGC936 6.0 mg/kg (n=13): 0 (0 to 0); Dose Expansion - TNBC: IMGC936 6.0 mg/kg (n=6): 0 (0 to 0).

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

Dose Escalation and Dose Expansion Phase: Maximum Study Drug Concentration (Cmax) [Schedule A: Cycle 1 Day 1 (C1D1), C3D1; Schedule B: C1D1, C1D15]. Geometric Mean, micrograms/milliliter (μg/mL) (Geometric Coefficient of Variation). C1D1: Dose Escalation - Schedule A: IMGC936 0.5 mg/kg (n=3): 14.17 (22); Dose Escalation - Schedule A: IMGC936 1.0 mg/kg (n=3): 22.21 (5.6); Dose Escalation - Schedule A: IMGC936 2.0 mg/kg (n=3): 56.69 (14.2); Dose Escalation - Schedule A: IMGC936 4.0 mg/kg (n=3): 107.2 (9.6); Dose Escalation - Schedule A: IMGC936 5.0 mg/kg (n=3): 114.8 (30.7); Dose Escalation - Schedule A and Dose Expansion: IMGC936 6.0 mg/kg (n=29): 149.5 (21.6); Dose Escalation - Schedule A: IMGC936 7.0 mg/kg (n=9): 162.4 (23.7); Dose Escalation - Schedule B: IMGC936 2.0 mg/kg (n=3): 51.74 (9.8). C1D15: Dose Escalation - Schedule B: IMGC936 2.0 mg/kg (n=3): NA (NA) [Not calculable due to insufficient number of valid PK parameters]. C3D1: Dose Escalation - Schedule A: IMGC936 0.5 mg/kg (n=3): NA (NA) [Not calculable due to insufficient number of valid PK parameters]; Dose Escalation - Schedule A: IMGC936 2.0 mg/kg (n=3): NA (NA) [Not calculable due to insufficient number of valid PK parameters]; Dose Escalation - Schedule A: IMGC936 5.0 mg/kg (n=3): NA (NA) [Not calculable due to insufficient number of valid PK parameters]; Dose Escalation - Schedule A and Dose Expansion: IMGC936 6.0 mg/kg (n=29): 168.4 (16.4); Dose Escalation - Schedule A: IMGC936 7.0 mg/kg (n=9): NA (NA) [Not calculable due to insufficient number of valid PK parameters].

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

Dose Escalation and Dose Expansion Phase: Number of Participants With Antidrug Antibodies (ADA) [Up to approximately 3 years]. Count Of Participants, Participants. Dose Escalation - Schedule A: IMGC936 0.5 mg/kg (n=3): 3; Dose Escalation - Schedule A: IMGC936 1.0 mg/kg (n=3): 1; Dose Escalation - Schedule A: IMGC936 2.0 mg/kg (n=3): 1; Dose Escalation - Schedule A: IMGC936 4.0 mg/kg (n=3): 0; Dose Escalation - Schedule A: IMGC936 5.0 mg/kg (n=3): 1; Dose Escalation - Schedule A: IMGC936 6.0 mg/kg (n=10): 2; Dose Escalation - Schedule A: IMGC936 7.0 mg/kg (n=9): 0; Dose Escalation - Schedule B: IMGC936 2.0 mg/kg (n=3): 1; Dose Expansion - NSCLC: IMGC936 6.0 mg/kg (n=13): 3; Dose Expansion - TNBC: IMGC936 6.0 mg/kg (n=6): 1.

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

Dose Escalation Phase: ORR - Percentage of Participants With Objective Response as Assessed by the Investigator Using RECIST v1.1 [Up to approximately 3 years]. Number, percentage of participants (95% Confidence Interval). Dose Escalation - Schedule A: IMGC936 0.5 mg/kg (n=3): 0 (0 to 0); Dose Escalation - Schedule A: IMGC936 1.0 mg/kg (n=3): 0 (0 to 0); Dose Escalation - Schedule A: IMGC936 2.0 mg/kg (n=3): 0 (0 to 0); Dose Escalation - Schedule A: IMGC936 4.0 mg/kg (n=3): 0 (0 to 0); Dose Escalation - Schedule A: IMGC936 5.0 mg/kg (n=3): 0 (0 to 0); Dose Escalation - Schedule A: IMGC936 6.0 mg/kg (n=10): 0 (0 to 0); Dose Escalation - Schedule A: IMGC936 7.0 mg/kg (n=9): 0 (0 to 0); Dose Escalation - Schedule B: IMGC936 2.0 mg/kg (n=3): 0 (0 to 0).

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

Dose Escalation and Dose Expansion Phase: Duration of Response (DOR) as Assessed by the Investigator Using RECIST v1.1 [Up to approximately 3 years]. Median, months (Full Range). Dose Escalation - Schedule A: IMGC936 0.5 mg/kg (n=3): NA (NA to NA) [No participant had response; hence, data could not be calculated.]; Dose Escalation - Schedule A: IMGC936 1.0 mg/kg (n=3): NA (NA to NA) [No participant had response; hence, data could not be calculated.]; Dose Escalation - Schedule A: IMGC936 2.0 mg/kg (n=3): NA (NA to NA) [No participant had response; hence, data could not be calculated.]; Dose Escalation - Schedule A: IMGC936 4.0 mg/kg (n=3): NA (NA to NA) [No participant had response; hence, data could not be calculated.]; Dose Escalation - Schedule A: IMGC936 5.0 mg/kg (n=3): NA (NA to NA) [No participant had response; hence, data could not be calculated.]; Dose Escalation - Schedule A: IMGC936 6.0 mg/kg (n=10): NA (NA to NA) [No participant had response; hence, data could not be calculated.]; Dose Escalation - Schedule A: IMGC936 7.0 mg/kg (n=9): NA (NA to NA) [No participant had response; hence, data could not be calculated.]; Dose Escalation - Schedule B: IMGC936 2.0 mg/kg (n=3): NA (NA to NA) [No participant had response; hence, data could not be calculated.]; Dose Expansion - NSCLC: IMGC936 6.0 mg/kg (n=13): NA (NA to NA) [No participant had response; hence, data could not be calculated.]; Dose Expansion - TNBC: IMGC936 6.0 mg/kg (n=6): NA (NA to NA) [No participant had response; hence, data could not be calculated.].

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

Dose Expansion Phase: Progression-Free Survival (PFS) as Assessed by the Investigator Using RECIST v1.1 [Up to approximately 3 years]. Median, months (Full Range). Dose Expansion - NSCLC: IMGC936 6.0 mg/kg (n=13): 2.7 (0.7 to 6.7); Dose Expansion - TNBC: IMGC936 6.0 mg/kg (n=6): 1.2 (0.0 to 2.4).

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

Dose Expansion Phase: Number of Participants With TEAEs, SAEs, and IMGC936 Related TEAEs That Led to Discontinuation [Up to approximately 3 years]. Count Of Participants, Participants. Any TEAEs: Dose Expansion - NSCLC: IMGC936 6.0 mg/kg (n=13): 13; Dose Expansion - TNBC: IMGC936 6.0 mg/kg (n=6): 6. SAEs: Dose Expansion - NSCLC: IMGC936 6.0 mg/kg (n=13): 4; Dose Expansion - TNBC: IMGC936 6.0 mg/kg (n=6): 2. IMGC936 related TEAEs That Led to Discontinuation: Dose Expansion - NSCLC: IMGC936 6.0 mg/kg (n=13): 1; Dose Expansion - TNBC: IMGC936 6.0 mg/kg (n=6): 1.